# Lidakang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lidakang

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.lidakang.com
- Total disclosed funding: $16M
- Latest round: Series A (Jan 31, 2019)
- Investors on record: 2

## About

Beijing Lidakang Technology Co., Ltd. is a company focused on providing advanced surgical solutions designed to enhance the safety and efficiency of surgical procedures for medical professionals.Founded in 1998 and headquartered in Beijing, China, Lidakang specializes in developing innovative surgical solutions. The company successfully raised CNY 110 million in Series A funding on January 31, 2019, from Beijing Hetang Investment Management and Shenzhen Capital Group, which marks a key milestone in its growth.Beijing Lidakang Technology Co., Ltd. specializes in providing comprehensive surgical solutions tailored for medical professionals. Their core product offerings are designed to assist doctors in a variety of surgical procedures, enhancing both the efficacy and safety of patient care. The company’s solutions are aimed at addressing specific challenges in the surgical field, with a focus on improving operational efficiency and patient outcomes. The products cater to hospitals and clinics, particularly in urban regions of China, with a notable emphasis on enhancing surgical precision and reducing recovery times for patients. Through innovative technology and robust support services, Lidakang builds relationships with healthcare providers, facilitating better surgical practices across the medical community.The revenue structure of Beijing Lidakang Technology Co., Ltd. is based on direct sales and partnerships within the healthcare sector. The company engages primarily in B2B transactions, supplying its surgical solutions directly to hospitals and medical institutions. These transactions involve negotiated contracts detailing the procurement of medical devices and surgical instruments tailored to the needs of healthcare providers. The pricing structure is determined by the complexity and specificity of the products offered, with flagship items commanding premium pricing due to their advanced features and benefits. By establishing long-term relationships with clients, Lidakang ensures a steady revenue stream through repeat business and ongoing support services.Lidakang plans to utilize the CNY 110 million raised in Series A funding to advance its product lineup and expand into new markets. The company is developing new surgical technologies aimed at launching in the coming years, focusing on improving surgical outcomes and operational efficiencies. Additionally, Lidakang is targeting expansion into international markets to broaden its reach, with specific interest in Southeast Asia by 2025. This strategic approach aims to enhance its product offerings and establish a stronger presence in the global healthcare landscape.

## Funding rounds

- Series A, Jan 31, 2019, $16M — Shenzhen Capital Real Estate Fund, Beijing Hetang Investment Management

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Beijing Hetang Investment Management — Series A